Clinical trials: in Pakistan
Aneurysm, Aneurysm, Ruptured
SEAL™ME: Saccular Endovascular Aneurysm Lattice System Multicenter Enrollment Global Registry
Prospective, international, single-arm, multicenter, registry study. Patients presenting with evidence of Wide Neck unruptured or ruptured intracranial aneurysm (≤ 20 mm in widest diameter) requiring treatment will be enrolled…
- Trial name
- SEAL™ME (NCT05880680)
- Testing
- SEAL Device
- Where
- 4 sites in Colombia, New Zealand and 2 more
- Volunteers
- 200 people
- Sponsor
- Galaxy Therapeutics INC
Liver Fat, Liver Fibrosis
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease…
- Conditions
- Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes
- Trial name
- Ertu-NASH (NCT05644717)
- Testing
- Ertugliflozin 5 mg, 15mg
- Where
- Pakistan
- Volunteers
- 164 people
- Sponsor
- Getz Pharma
Neoplasms, Breast
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
This was a four-arm (parallel group) randomized, open-label, multicenter Phase 3 study to investigate the use of a combination of Lapatinib and Trastuzumab, a sequence of Trastuzumab followed by Lapatinib, and Lapatinib alone…
- Trial name
- ALTTO (NCT00490139)
- Testing
- Lapatinib, Trastuzumab
- Where
- 924 sites in United States, Argentina and 42 more
- Volunteers
- 8,381 people
- Sponsor
- Novartis Pharmaceuticals
Efficacy, Safety
Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study
Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study to evaluate the efficacy, safety and tolerability of Ertugliflozin and Sitagliptin Con-initiation in patients with Type II…
- Conditions
- Efficacy, Safety, Tolerability
- Trial name
- CEASE (NCT05556291)
- Testing
- Combinations of Oral Blood Glucose Lowering Drugs
- Where
- 3 sites in Pakistan
- Volunteers
- 190 people
- Sponsor
- Getz Pharma
Influenza, Human
Efficacy Study With QIVc in Pediatric Subjects
This phase 3 clinical study is a randomized, observer-blind, multicenter study of QIVc versus a non-influenza vaccine in subjects 6 months though 47 months of age.
- Trial name
- NCT03932682
- Testing
- QIVc, Comparator
- Where
- 74 sites in Bangladesh, Bulgaria and 13 more
- Volunteers
- 5,723 people, healthy volunteers welcome
- Sponsor
- Seqirus
Primary Dysmenorrhea
Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea
Dysmenorrhea is characterized as excruciating menstrual cramps of uterine origin and is one of the most prevalent gynecological illnesses.
- Trial name
- NCT06317064
- Testing
- Ibuprofen and Aprepitant
- Where
- Pakistan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lahore Medical Research Center, LLP
Invasive Candidiasis, Mucocutaneous Candidiasis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or…
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis
- Trial name
- FURI (NCT03059992)
- Testing
- Ibrexafungerp
- Where
- 37 sites in United States, Austria and 6 more
- Volunteers
- 233 people
- Sponsor
- Scynexis, Inc.
Chronic Neck Pain
Clinical Response of Nuberol Forte in Chronic Neck Pain in Routine Rehabilitation Centers
Globally, the prevalence of neck pain ranges from 16.7% to 75.1%. Despite conducting multiple studies on specific subject pools in Pakistan, primarily focusing on professional-related neck pain, there is a lack of accurate data…
- Trial name
- "NOTICE" (NCT06628466)
- Testing
- Nuberol Forte
- Where
- Pakistan
- Volunteers
- 150 people
- Sponsor
- The Searle Company Limited Pakistan
Diabetes Mellitus, Type 2
A Research Study, Looking at the Characterization of Treatment Intensified (Add on to Metformin) Real-world Adult Population With Type 2 Diabetes Mellitus in India, Pakistan and Thailand.
This study aims to describe demographics, clinical, treatment and healthcare resource utilization characteristics with a particular focus on those relating to cardiovascular disease in selected treatment intensified patients with…
- Trial name
- CONVERGE (NCT05542420)
- Testing
- No treatment given
- Where
- 3 sites in India, Pakistan and 1 more
- Volunteers
- 3,000 people
- Sponsor
- Novo Nordisk A/S
COVID-19
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have…
- Trial name
- NCT05636319
- Testing
- ABO1020
- Where
- 25 sites in Indonesia, Pakistan and 2 more
- Volunteers
- 14,168 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Rabies, Prevention
A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried
This is a phase III, randomized, comparator-controlled, double-blind, multicenter study to evaluate lot-to-lot consistency of three lots of a PIKA Rabies Vaccine, immunogenicity and safety in healthy adults using a post-exposure…
- Trial name
- NCT05667974
- Testing
- PIKA Rabies Vaccine (Vero Cell) for Human use, Freeze-dried, Chirorab
- Where
- 7 sites in Pakistan, Philippines
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
Candidiasis, Invasive, Candidemia
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
This is a multicenter, open-label, non-comparator, single-arm study to evaluate the efficacy, safety, tolerability and PK (pharmacokinetics) of oral SCY-078 as an emergency use treatment for patients with a documented Candida…
- Trial name
- CARES (NCT03363841)
- Testing
- SCY-078
- Where
- 12 sites in United States, India and 2 more
- Volunteers
- 30 people
- Sponsor
- Scynexis, Inc.
Moderate to Severe Ulcerative Colitis
A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT04700449
- Testing
- Double-Blind 0.2mg CBP-307, Open-label CBP-307, Double-Blind 0.1mg CBP-307
- Where
- 66 sites in United States, China and 2 more
- Volunteers
- 145 people
- Sponsor
- Connect Biopharm LLC
Cough
Clinical Response of Syrup Hydryllin® in Pakistani Subjects With Cough in Routine Practice
A cough is one of the most common medical complaints accounting for as many as 30 million clinical visits per year. It is the single most prevalent symptom on presentation to a physician's office.
- Trial name
- HYD-EFFECT (NCT05129761)
- Testing
- Syrup Hydryllin
- Where
- Pakistan
- Volunteers
- 320 people
- Sponsor
- The Searle Company Limited Pakistan
Sudden Cardiac Arrest, Acute Myocardial Infarction
Improve SCA Bridge Study
The purpose of the Improve SCA Bridge study is to characterize the care pathway flow of post-acute myocardial infarction (MI) patients as a result of standard assessments of left ventricular ejection fraction (LVEF) in the acute…
- Trial name
- NCT03715790
- Testing
- EP referred group, Non-Referred group
- Where
- 52 sites in Bangladesh, Brunei and 14 more
- Volunteers
- 1,491 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Healthy Infants
Infant Feeding Practice and Gut Comfort Study
Multi-country, cross-sectional, observational study in diverse geographic locations all over the world.
- Trial name
- NCT03703583
- Testing
- There is no intervention in this observational study.
- Where
- 16 sites in Egypt, India and 4 more
- Volunteers
- 2,804 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
COVID-19
Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above
This study is a global multicenter, randomized, double-blind, placebo -controlled, adaptive designed phase Ⅲ clinical trial, in order to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine…
- Trial name
- NCT04526990
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- 74 sites in Argentina, Chile and 3 more
- Volunteers
- 44,247 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Diabetes Mellitus
GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients.
- Trial name
- NCT00909051
- Testing
- Acarbose (Glucobay, BAYG5421)
- Where
- 16 sites in Algeria, Bosnia and Herzegovina and 14 more
- Volunteers
- 15,729 people
- Sponsor
- Bayer
Safety, Tolerability
Phase 1 Clinical Trial of RHN-001 in Healthy Adult Volunteers
The goal of this clinical Trial is to assess the safety, tolerability and Pharmacokinetic profile of 750 mg single oral dose of RHN-001 and 1500 mg of RHN-001 administered orally in fasted and fed conditions in healthy adult…
- Conditions
- Safety, Tolerability, Pharmacokinetics
- Trial name
- NCT05847218
- Testing
- RHN-001 (one tablet 750mg), RHN-001 (750mg * 2 Tablets)
- Where
- Pakistan
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- RH Nanopharmaceuticals
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study
A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine…
- Trial name
- COVID-19 (NCT05096832)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01), Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
- Where
- 18 sites in Malaysia, Pakistan
- Volunteers
- 10,381 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.